Physician profile
Keith R Jackson
NPI 1124116041
$1,541.97
in general payments reported to CMS, 2019-2025
14 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.68 · 2021: $58.72 · 2022: $260 · 2023: $257 · 2024: $588 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.96 |
| Education | $114.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.83 | 2022-2025 | |
| Janssen Biotech, INC. | $309.45 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $250.73 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $133.02 | 2024 | Zoryve |
| Amgen INC. | $111.48 | 2025 | Otezla, Otezla |
| Pfizer INC. | $108.42 | 2022-2024 | |
| Incyte Corporation | $95.72 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $51.26 | 2024-2025 | |
| Lilly USA, LLC | $38.40 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $34.17 | 2022-2023 | Valchlor |
| Regeneron Healthcare Solutions, INC. | $30.19 | 2025 | Libtayo |
| Genentech USA, INC. | $21.30 | 2022 | |
| Acclarent, INC | $20.32 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.